Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Macrolide showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease
It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).
1 finding from 1 review
Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease
Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with macrolide (low certainty).
1 finding from 1 review
Total number of paracetamol (acetaminophen) with codeine (Tylenol) tablets · Adults over 18 years presenting with a single tooth with a clinical diagnosis of irreversible pulpitis
Systemic antibiotic (oral penicillin 500 mg) plus analgesic showed no clear difference in total number of paracetamol (acetaminophen) with codeine (Tylenol)… compared with placebo plus analgesic (low certainty).
1 finding from 1 review
Relief of pain · Adults over 18 years presenting with a single tooth with a clinical diagnosis of irreversible pulpitis
The review found no eligible studies for this question.
1 finding from 1 review
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
Glutaraldehyde + zinc oxide and eugenol (ZOE) showed no clear difference in clinical failure compared with full strength formocresol (FC); GRADE not reported.
1 finding from 1 review
Radiological failure · Children with extensive decay involving the dental pulp in primary teeth
Metapex (calcium hydroxide/iodoform) showed no clear difference in radiological failure compared with endoflas chlorophenol free (Endoflas-CF); GRADE not reported.
1 finding from 1 review
Radiological failure · Children with extensive decay involving the dental pulp in primary teeth
Low-level laser therapy (LLLT) + calcium hydroxide showed no clear difference in radiological failure compared with formocresol (FC); GRADE not reported.
1 finding from 1 review
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
Biodentine showed no clear difference in clinical failure compared with calcium hydroxide (CH); GRADE not reported.
1 finding from 1 review
Clinical failure · Children with extensive decay involving the dental pulp in primary teeth
1 finding from 1 review
Radiological failure · Children with extensive decay involving the dental pulp in primary teeth
Calcium hydroxide (CH) probably leads to higher radiological failure compared with formocresol (FC) (moderate certainty).
2 findings from 1 review